Table 1.

Harms of leuprotelin versus placebo in one RCT (65 women) (see text).

Harms	Gonadorelin		Placebo
	Outcome	Population	%		Outcome	Population	%	RR*	95% CI*
Vasomotor flushes	52	63	83%		5	65	8%	10.7	4.6 to 25.1
Vaginitis	11	63	17%		0	65	0%
Arthralgia/mialgia	9	63	14%		0	65	0%
Asthenia	10	63	16%		3	65	5%	3.4	0.97 to 996
Peripheral oedema	7	63	11%		1	65	2%	7.2	0.9 to 57
Insomnia	6	63	10%		0	65	0%
Nausea	6	63	10%		1	65	2%	6.2	0.8 to 50
Emotional ability /nervousness	5	63	8%		1	65	2%	5.2	0.6 to 42.9
Depression	7	63	11%		2	65	3%	3.6	0.8 to 16.7
Headaches	18	63	29%		13	65	20%	1.4	0.8 to 2.7
Decreased libido	2	63	3%		0	65	0%

*BMJ Clinical Evidence recalculation.